{
    "clinical_study": {
        "@rank": "77388", 
        "arm_group": [
            {
                "arm_group_label": "P-gp probe substrate(digoxin)+regorafenib", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Group B: BCRP probe substrate (rosuvastatin) + regorafenib", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate :\n      P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by\n      comparing their  Area under time curve (AUC(0-24)) and maximum drug concentration (Cmax) on\n      Day -7 and Cycle 1 or Cycle 2 Day 15 of regorafenib in cancer patients"
        }, 
        "brief_title": "Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Inclusion Criteria:\n\n          -  The following criteria apply to ALL patients starting the study treatment:\n\n               -  Patients with histologically confirmed, locally advanced or metastatic solid\n                  tumors refractory to standard therapy or in whom regorafenib is considered a\n                  standard treatment.\n\n               -  Male or  Female Caucasian patients >/= 18 years of age\n\n               -  Women of childbearing potential and men must agree to use adequate contraception\n                  before entering the program until at least 8 weeks after the last study drug\n                  administration.\n\n               -  Life expectancy of at leat 12 weeks\n\n               -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n               -  Adequate bone marrow and liver function\n\n               -  Estimated creatinine clearance (CLcr) \u2265 30 mL/min as calculated using the\n                  Cockroft-Gault (C-G) equation.\n\n               -  Thyroid Stimulating Hormone(TSH) within normal ranges.\n\n          -  The following inclusion criteria apply to Group A (digoxin + regorafenib) patients\n             ONLY:\n\n               -  Potassium, magnesium and calcium blood levels within normal range according to\n                  the local laboratory.\n\n          -  The following inclusion criteria apply to Group B (rosuvastatin + regorafenib)\n             patients ONLY:\n\n               -  Signed genetic informed consent. Patients must be able to understand and willing\n                  to sign the written informed consent intended to screen for BCRP and OATP1B1\n                  polymorphisms.\n\n          -  Exclusion Criteria:\n\n          -  For ALL patients\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             before start of study medication.\n\n          -  Non-healing wound, skin ulcer, or bone fracture.\n\n          -  Ongoing or active infection.\n\n          -  Other anticancer treatment.\n\n          -  Patients unable to swallow oral medications\n\n          -  For Group A (digoxin + regorafenib):\n\n               -  Family history of sudden cardiac death.\n\n          -  For Group B (rosuvastatin + regorafenib):\n\n               -  Patients with porphyria.\n\n               -  Patients with intestinal or urinary obstructions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106845", 
            "org_study_id": "16674", 
            "secondary_id": "2013-003613-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "P-gp probe substrate(digoxin)+regorafenib", 
                "description": "Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib", 
                "intervention_name": "Digoxin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group B: BCRP probe substrate (rosuvastatin) + regorafenib", 
                "description": "Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "P-gp probe substrate(digoxin)+regorafenib", 
                    "Group B: BCRP probe substrate (rosuvastatin) + regorafenib"
                ], 
                "description": "Once daily orally 160 mg (4 tablets 40 mg)", 
                "intervention_name": "Regorafenib (Stivarga, BAY73-4506)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Digoxin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Regorafenib", 
            "Probe substrates", 
            "Pharmacokinetics", 
            "Cancer", 
            "Safety", 
            "Advanced solid malignant tumors"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg", 
                        "zip": "79106"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "60488"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Herne", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "44625"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Multi-center, Non-randomized, Open Label, Drug-drug-interaction Study to Determine the Effect of Multiple Doses of Regorafenib (BAY 73-4506) on the Pharmacokinetics of Probe Substrates of Transport Proteins P-gp (Digoxin; Group A) and BCRP (Rosuvastatin; Group B) in Patients With Advanced Solid Malignant Tumors", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_contact_backup": {
            "last_name": "For trial location information (Phone Menu Options '3' or '4')", 
            "phone": "(+)1-888-84 22937"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for Digoxin", 
                "safety_issue": "No", 
                "time_frame": "On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15"
            }, 
            {
                "measure": "Maximum drug concentration (Cmax) in plasma for Digoxin", 
                "safety_issue": "No", 
                "time_frame": "On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15"
            }, 
            {
                "measure": "Maximum drug concentration (Cmax) in plasma for  rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106845"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumor Response following RECIST criteria", 
                "safety_issue": "No", 
                "time_frame": "From first dose up to 3 months after end of treatment"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dose"
            }, 
            {
                "measure": "Number of participants with drug related adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dose"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}